Novo Holdings Buys 4.18 Million Hemab Shares Post‑Upsized IPO – What It Means for Rare‑Disease Biotech
Novo Holdings buys 4.18 M Hemab shares post‑IPO, backing its rare‑disorder pipeline and signaling long‑term confidence in Phase‑2 candidates HMB‑001 & HMB‑002.
3 minutes to read